Samsung Biologics announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100 percent of Human Genome Sciences (HGS) from GSK. The move secures Samsung Biologics' first US-based manufacturing site.

Located in Rockville, Maryland, the facility encompasses two cGMP manufacturing plants with a combined 60,000 litres of drug substance capacity, supporting both clinical and commercial production from small to large scale. Existing products will continue to be manufactured at the site, and the company plans to make additional investments to expand the site's capacity and upgrade technology to further support a more resilient US supply chain for critical biologic medicines.

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for USD 280 million. The company will also retain more than 500 employees at the site to ensure operational continuity and stability. By integrating this facility into our global network, it will provide clients with flexible, multi-site options in both the US and Korea to ensure that life-saving therapeutics are reliably available to American patients.

"This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the US. The investment will enable us to deepen our collaboration with federal, state and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics. This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact," said John Rim, CEO and President, Samsung Biologics.

Samsung Biologics has established a proven track record of operational and construction excellence through on-time completion of its Bio Campus I and II, and also recently secured land for Bio Campus III, which will house distinct R&D and manufacturing programmes for new modalities. With 785,000 litres of capacity across five plants, the company continues to advance its diversified portfolio spanning monoclonal antibodies, Antibody Drug Conjugates (ADCs), mRNA, organoid-based services and next-generation therapies.

Regis Simard, President, Global Supply Chain, GSK, said, "Today's agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK's supply chain resilience. Along with GSK's recent commitment to invest USD 30 billion in R&D and manufacturing in the US over the next five years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site."?